for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Acorda Therapeutics Inc

ACOR.O

Latest Trade

0.65USD

Change

-0.02(-2.25%)

Volume

1,785,381

Today's Range

0.64

 - 

0.68

52 Week Range

0.42

 - 

2.78

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Acorda Reports Third Quarter 2020 Financial Results

Nov 3 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS.Q3 NON-GAAP LOSS PER SHARE $0.23.Q3 GAAP EARNINGS PER SHARE $0.05.

Acorda Therapeutics Says Co Entitled To Receive $15 Million Milestone Payment

Oct 19 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA THERAPEUTICS INC - ENTITLED TO RECEIVE A $15 MILLION MILESTONE PAYMENT FROM BIOGEN INTERNATIONAL GMBH.ACORDA THERAPEUTICS INC - WILL RETAIN APPROXIMATELY $14 MILLION OF MILESTONE PAYMENT NET OF COMPANY'S PAYMENT OBLIGATIONS TO ANOTHER PARTY.ACORDA THERAPEUTICS INC - EXPECTS TO RECEIVE PAYMENT BY END OF OCTOBER 2020..

Acorda Therapeutics Inc Files For Mixed Shelf Of Upto $100 Mln

Sept 11 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA THERAPEUTICS INC FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING.

Acorda Reports Second Quarter 2020 Financial Results

Aug 4 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.35.Q2 GAAP LOSS PER SHARE $0.37.Q2 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.FOR FULL-YEAR 2020, ACORDA CONTINUES TO EXPECT AMPYRA NET REVENUE TO BE $85 - $110 MILLION.FOR FULL-YEAR 2020, ACORDA CONTINUES TO EXPECT OPERATING EXPENSES TO BE $170 - $180 MILLION.

Acorda Therapeutics Files For Resale Of Up To 8.7 Mln Shares Of Common Stock

June 29 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA THERAPEUTICS INC FILES FOR RESALE OF UP TO 8.7 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.

Acorda Reports First Quarter 2020 Financial Results And Provides Business Update

May 5 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 NON-GAAP LOSS PER SHARE $0.51.Q1 GAAP LOSS PER SHARE $0.14.REITERATES 2020 AMPYRA NET REVENUE GUIDANCE AND OPERATING EXPENSE GUIDANCE.WITHDRAWS 2020 INBRIJA NET REVENUE GUIDANCE DUE TO ONGOING COVID-19 PANDEMIC.ACORDA THERAPEUTICS - AT MARCH 31, HAD CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS,RESTRICTED CASH OF $126.3 MILLION VERSUS $168.9 MILLION AT YEAR END 2019.FOR FULL-YEAR 2020, ACORDA CONTINUES TO EXPECT AMPYRA NET REVENUE TO BE $85 - $110 MILLION.CONTINUES TO EXPECT INBRIJA PEAK SALES IN 2020 TO BE $300 MILLION - $500 MILLION.

Acorda Therapeutics Posts Q4 Earnings Per Share $1.38

Feb 13 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.Q4 GAAP EARNINGS PER SHARE $1.38.Q4 NON-GAAP LOSS PER SHARE $0.15.Q4 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.ACORDA THERAPEUTICS - TOTAL PRODUCT NET REVENUE FOR FULL YEAR 2020 IS EXPECTED TO BE $120 - $150 MILLION WITH TOTAL REVENUE EXPECTED TO BE $130 - $160 MILLION.FY2020 REVENUE VIEW $149.2 MILLION -- REFINITIV IBES DATA.

Acorda Therapeutics Files For Resale Of Up To 9.6 Mln Shares Of Common Stock

Jan 15 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA THERAPEUTICS INC FILES FOR RESALE OF UP TO 9.6 MILLION SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.

Acorda Sees Total Product Net Revenue For 2020 To Be $120 - $150 Mln

Jan 15 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::ACORDA PROVIDES 2019 HIGHLIGHTS AND 2020 GUIDANCE AT J.P. MORGAN HEALTHCARE CONFERENCE.TOTAL PRODUCT NET REVENUE FOR FULL YEAR 2020 IS EXPECTED TO BE $120 - $150 MILLION.TOTAL REVENUE FOR 2020 IS EXPECTED TO BE $130 - $160 MILLION..EXPECTED INBRIJA U.S. ANNUAL PEAK SALES FOR 2020 HAS BEEN REVISED TO $300 - $500 MILLION.AMPYRA NET REVENUE FOR FULL YEAR 2020 IS EXPECTED TO BE $85 - $110 MILLION.FY2020 REVENUE VIEW $143.9 MILLION -- REFINITIV IBES DATA.

Canyon Capital Advisors Reported A Passive Stake Of 14% In Acorda Therapeutics Inc As Of Dec 31, 2019 - SEC Filing

Jan 13 (Reuters) - Acorda Therapeutics Inc <ACOR.O>::CANYON CAPITAL ADVISORS LLC REPORTED A PASSIVE STAKE OF 14% IN ACORDA THERAPEUTICS INC AS OF DEC 31, 2019 - SEC FILING.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up